A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH.
Sharma M, et al. Among authors: hosing cm.
Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1.
Cancer. 2012.
PMID: 21887685
Free PMC article.
Clinical Trial.